Aviel Ronen Sarit

Medicine & Life Sciences

1. Adenocarcinoma 100%
2. Neoplasms 96%
3. Carcinoma 76%
4. Non-Small Cell Lung Carcinoma 73%
5. Adenosquamous Carcinoma 55%
6. Fallopian Tubes 53%
7. Survival 50%
8. Ovarian Neoplasms 48%
9. Adjuvant Chemotherapy 46%
10. Ovulation 45%
11. Mutation 40%
12. Fertility Preservation 38%
13. AICDA (activation-induced cytidine deaminase) 37%
14. Squamous Cell Carcinoma 32%
15. Biomarkers 32%
16. Mucins 30%
17. Drug Therapy 30%
18. Papillomaviridae 29%
19. Neuroendocrine Carcinoma 28%
20. Small Cell Lung Carcinoma 28%
21. Mucinous Adenocarcinoma 27%
22. Recurrence 27%
23. Pathology 25%
24. Vinorelbine 24%
25. Ovary 24%
26. Trefoil Factor-2 23%
27. Gm(m) 23%
28. Immunohistochemistry 22%
29. Epithelial Cells 22%
30. Calcifying Epithelial Odontogenic Tumor 22%
31. DNA 21%
32. Lung 20%
33. Gene Dosage 20%
34. ErbB Receptors 20%
35. Carcinogenesis 19%
36. Transplantation 19%
37. Racemases and Epimerases 19%
38. temsirolimus 19%
39. Glypicans 18%
40. Granulosa Cell Tumor 18%
41. Liquid Biopsy 17%
42. Comparative Genomic Hybridization 17%
43. Heart Neoplasms 17%
44. Genome 17%
45. Chordoma 17%
46. LH Receptors 17%
47. Foreign-Body Reaction 17%
48. Poly(ADP-ribose) Polymerase Inhibitors 16%
49. Fractals 16%
50. Bronchiolo-Alveolar Adenocarcinoma 16%